Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop

  • Roger A. Barker
  • , Mart Saarma
  • , Clive N. Svendsen
  • , Catherine Morgan
  • , Alan Whone
  • , Massimo S. Fiandaca
  • , Matthias Luz
  • , Krystof S. Bankiewicz
  • , Brian Fiske
  • , Lyndsey Isaacs
  • , Arthur Roach
  • , Thomas Phipps
  • , Jeffrey H. Kordower
  • , Emma L. Lane
  • , Henri J. Huttunen
  • , Aideen Sullivan
  • , Gerard O'Keeffe
  • , Valeria Yartseva
  • , Howard Federoff

Research output: Contribution to journalReview articlepeer-review

Abstract

In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019.1 This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial.2 We then concluded with our recommendations on how GF studies in PD should develop going forward.

Original languageEnglish
Pages (from-to)1659-1676
Number of pages18
JournalJournal of Parkinson's Disease
Volume14
Issue number8
DOIs
Publication statusPublished - 1 Nov 2024

Keywords

  • animal models
  • end points
  • GDNF
  • gene therapy
  • Parkinson's
  • patient voice
  • trials
  • workshop

Fingerprint

Dive into the research topics of 'Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop'. Together they form a unique fingerprint.

Cite this